Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic by Jacobs, TQ & Ross, A
Original Research: Adverse effects profile of multidrug-resistant tuberculosis treatment
531 Vol 54 No 6S Afr Fam Pract 2012
Introduction
Tuberculosis reports that were submitted by South Africa 
to the World Health Organization (WHO) indicate a fivefold 
increase in the notification of tuberculosis over the last 20 
years.1 South Africa and Swaziland have the highest tubercu-
losis notification rates in the world, with an annual incidence 
of about 1% of their populations.1 Despite highly effective 
drugs, morbidity and mortality due to Mycobacterium tu-
berculosis are increasing in South Africa, and this is fuelled 
by the widespread human immunodeficiency virus (HIV) 
epidemic.2 Just under 2% of new patients with tuberculosis 
and 6.7% of retreatment patients have multidrug-resistant 
tuberculosis.2 Multidrug-resistant tuberculosis is defined as 
Mycobacterium tuberculosis that is resistant to both iso-
niazid and rifampicin, with or without resistance to other 
drugs.3 Given the number of patients with tuberculosis, this 
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equates to a large burden of multidrug-resistant tuberculosis 
in South Africa. There were 2 140 new multidrug-resistant 
tuberculosis cases in South Africa from 2004-2007.4 In its 
policy guidelines, the Department of Health has noted that 
the limited number of available second-line drugs imposes 
limitations on the design of adequate multidrug-resistant tu-
berculosis treatment regimens.2 The choice of drugs may be 
further restricted by adverse events that are experienced by 
patients.5 Despite anecdotal reports of adverse events that 
relate to multidrug-resistant tuberculosis treatment, to date, 
only a few studies describing the extent of this problem 
have been undertaken in South Africa.6 A description of the 
adverse events by data extraction and analysis could assist 




The King George V Hospital Outpatient Multidrug-Resistant 
Tuberculosis and Extensively Drug-Resistant Tuberculosis 
Clinic in Durban was selected as the study site. This clinic 
serves the Ethekwini Municipality, and some surrounding 
districts that do not have their own multidrug-resistant 
tuberculosis and extensively drug-resistant tuberculosis 
units. Patients with proven culture resistance to both 
isoniazid and rifampicin, with or without resistance to 
other drugs, are referred to the King George V Hospital for 
initiation of multidrug-resistant tuberculosis management. 
The standard multidrug-resistant tuberculosis regimen 
consists of an intensive phase of at least six months taking 
four oral drugs and one injectable drug, followed by a 
continuation phase of 18 months or less taking the four 
oral drugs. The King George V Hospital uses kanamycin 
or amikacin (injectable), ofloxacin, ethionamide, terizidone 
and pyrazinamide during the intensive phase. Ethambutol, 
a first-line drug, is also often added. Most patients who 
are diagnosed with multidrug-resistant tuberculosis are 
admitted initially, and ideally, should remain as in-patients 
until they are sputum-negative. However, this is not possible 
in all cases due to the increasing numbers of patients and 
limited beds. Patients are usually discharged once they 
are medically stable to continue treatment as outpatients. 
Outpatient clinics are held twice weekly. All enrolled patients 
are required to attend once per month. On average, between 
1 400-1 800 patients are followed up at any given time, with 
150-280 attending the outpatient department clinic on any 
given day. In consultation with a bio-statistician, a sample 
size of 350 was selected, which represented 25% of the 
study population. Inclusion criteria were all clinic attendees 
who had completed the first six months of treatment. 
For the purposes of this study, adverse effects were defined 
as “any undesirable or harmful effect or effects known to 
be associated with or suspected to be associated with 
the administration of a certain drug or drugs”. Many of the 
adverse events of standard tuberculosis treatment may 
also occur with multidrug-resistant tuberculosis treatment. 
The majority of patients included in this study had recently 
been on, or were still on, standard tuberculosis treatment 
drugs, when they were changed over to multidrug-resistant 
tuberculosis treatment. Therefore, it was necessary to 
record any adverse events at the initial presentation, prior 
to starting multidrug-resistant tuberculosis treatment. In 
addition, any adverse events that developed during the first 
six months of multidrug-resistant tuberculosis treatment 
were also analysed. Attendees with extensively drug-
resistant tuberculosis, those on non-standard treatment 
regimens, non-compliant patients, and those who failed 
to attend regularly were excluded from the study. During 
July and August 2011, patient files were randomly selected 
from the record archives. Files are stored in several filing 
cabinets according to surname. Within each cabinet, files 
are randomly placed, depending on when the patient was 
seen in the clinic. The first 25 files in each cabinet were 
selected for analysis. In total, 405 files were reviewed, and 
350 files met the inclusion criteria.
An anonymous, retrospective record review was performed 
using a data capture form. This form was derived from 
WHO tuberculosis monitoring and reporting guidelines,7 
and adverse events profiles reported in other studies.8-11 
The WHO designed a system to identify adverse events 
that could be reliably diagnosed clinically. Although 
some adverse events, such as depression and anxiety, 
are not clearly defined, this is the method that is used in 
tuberculosis clinics in the majority of low-income countries 
to monitor and report adverse events. To compare results 
with existing studies, the WHO monitoring tool was used. 
The WHO advises that routine laboratory monitoring is 
not necessary.12 However, wherever available, supporting 
laboratory results were included. 
Data were entered into SPSS® version 19.0 (SPSS, Chicago, 
Illinois, USA), and analysed descriptively. Frequency tables 
were used to summarise categorical data, while quantitative 
data were assessed using summary statistics, such as 
mean, standard deviation and range. Cross tabulations 
and Pearson’s chi-square tests or Fisher’s exact tests were 
used to assess associations between HIV infection and 
adverse effects, or the use of highly active antiretroviral 
therapy (HAART) and adverse effects. A p-value < 0.05 was 
considered to be significant.
Ethical considerations
Permission to conduct this study was granted by the King 
George V Hospital management and the KwaZulu-Natal 
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Department of Health. Final ethics approval (BE 158/010) 
was granted by the Post Graduate Committee and the 
Biomedical Research Ethics Committee at the NR Mandela 
Medical School in Durban. 
Results
A total of 405 randomly selected patient files were reviewed, 
of which 350 records were eligible for inclusion in the 
study. Of those files that were not included in the analysis, 
45 pertained to patients with extensively drug-resistant 
tuberculosis, and this constituted 11.1% of the total 
sample. The study sample comprised 182 females and 168 
males, with a mean age of 35.65 years [standard deviation 
(SD) 11.24]. A single drug was omitted from the standard 
regimen in 18 (5%) patients. These patients continued to 
receive at least one multidrug-resistant tuberculosis drug 
from each drug class. In 13 cases, terizidone was omitted, 
but ethionamide, which is also an oral bacteriostatic agent, 
was continued. In five cases, ethambutol was omitted, but 
pyrazinamide, another first-line oral agent, was continued. 
As these are considered to be acceptable alternate 
regimens, these 18 patients were included in the study 
group. Of the 350 patients, the HIV status of 341 patients 
was documented. Of these, 254/341 (74.5%) were HIV 
positive, and 216/254 (85%) were concomitantly on HAART 
and multidrug-resistant tuberculosis treatment.
Adverse events were reported by 97 patients prior to 
initiating multidrug-resistant tuberculosis treatment. Of 
these patients, 84 were HIV positive (87%), 11 were HIV 
negative, and two had an unknown HIV status. Seventy-two 
of the 84 patients were HIV positive (76%) and on HAART, 
10 patients were not on HAART (p-value < 0.001), and 
there was no documentation with regard to HAART for the 
remaining two patients who were HIV positive.
With regard to exposure to previous tuberculosis treatment, 
31 patients with tuberculosis who were treatment-naïve 
were started on multidrug-resistant tuberculosis treatment, 
and not standard tuberculosis treatment, because of drug-
sensitivity testing prior to treatment (primary multidrug-
resistant tuberculosis treatment). Of the remaining 319 
patients, 127 (40%) were on standard first-line, and 143 
(45%) were on second-line, tuberculosis retreatment 
regimens, when they were found to have multidrug-resistant 
tuberculosis. (see Table I)
Patients who were diagnosed with multidrug-resistant 
tuberculosis, while being exposed to standard tuberculosis 
treatment for the first time, were significantly more likely to 
be HIV positive than HIV negative (p-value = 0.005). There 
was a statistically significant higher incidence of multidrug-
resistant tuberculosis in females compared to males, with 
an odds ratio of 2.49 (95% confidence interval 1.58-3.92; 
p-value < 0.001). Tuberculosis contact history and HIV status 
was significant in males (p-value = 0.027), but not in females 
(p-value = 0.068). Males who were HIV positive in this sub-
group were more likely to have a positive tuberculosis 
contact history than females who were HIV positive. 
Two hundred and eight-two patients (80.6%) developed 
one or more adverse events while on multidrug-resistant 
tuberculosis treatment. This group consisted of 210 (82.7%) 
of the patients who were HIV positive, and 67 (77%) of the 
patients who were HIV negative. The HIV status of the 
remaining five patients was unknown. These adverse events 
required either dose reduction, withdrawal of the suspected 
drug, or symptomatic treatment and monitoring. The higher 
incidence of adverse events in patients who were HIV 
positive, compared with patients who were HIV negative, 
was statistically significant for peripheral neuropathy 
(p-value < 0.001), psychosis and confusion (p-value = 0.04), 
hearing loss and vestibular disturbances (p-value = 0.047), 
and thyroid disease (p-value < 0.001). 
There was no statistically significant difference in the 
development of adverse events between patients who 
were HIV positive and who were on multidrug-resistant 
tuberculosis treatment and HAART, and those who were not 
on HAART (p-value = 0.432). However, when the likelihood 
ratio was calculated for individual adverse events, the 
majority of adverse events were found to be more likely to 
occur in patients who were HIV positive and on HAART, than 
Table I: Diagnosis of multidrug-resistant tuberculosis in relation to the 
patient’s tuberculosis treatment regimen at the time
Diagnosed with multidrug-resistant 
tuberculosis (excluding the 31 de novo patients 
with multidrug-resistant tuberculosis)
No of patients 
(n = 319)
While on standard first-line tuberculosis treatment 127
During first exposure to standard tuberculosis 
retreatment regimen with second-line drugs
143
During second exposure to standard tuberculosis 
retreatment regimen with second-line drugs
46
During third exposure to standard tuberculosis 
retreatment regimen with second-line drugs
3
Table II: Likelihood ratios of adverse events occurring in patients who 
were HIV positive and on HAART, compared with those who were not 
on HAART
Adverse effect Likelihood ratio
Seizures 4.3
Peripheral neuropathy 1.99
Hearing loss and vestibular disturbances 6.6
Psychoses and confusion 1.91
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in those who were not on HAART. Table II lists the likelihood 
ratios of specific adverse events in patients on HAART.
Patients who were on stavudine (D4T)-containing regimens 
accounted for 56% (52 cases) of peripheral neuropathy, 
40% (20 cases) of nausea and vomiting, and 70% (14 
cases) of upper abdominal pain and dyspepsia. Patients on 
efavirenz (EFV)-containing regimens accounted for 60% (3 
cases) of seizures and 92.3% (12 cases) of psychoses or 
confusion. Twelve patients on regimens containing EFV or 
nevirapine (NVP) accounted for the majority of cases with 
skin rashes and dermatological effects (90%).
The most frequently occurring adverse events in 
descending order of frequency were hearing loss and 
vestibular disturbance (28.7%); peripheral neuropathy 
(23.2%); gastrointestinal disturbances, i.e. diarrhoea, 
nausea and vomiting (20.5%); arthralgia (15.9%); rashes 
and dermatological effects (other than Stevens-Johnson 
syndrome) (14%); abdominal pain and dyspepsia (10.3%); 
and psychoses and confusion (8.3%). Table III lists the 
frequency of all the adverse effects reported, according to 
HIV status and concomitant HAART and multidrug-resistant 
tuberculosis treatment. 
Thirty-six patients (10.3%) had abnormal liver enzyme 
biochemistry prior to initiation of multidrug-resistant 
tuberculosis treatment. Seventeen of these patients had 
cholestatic obstruction [(gamma-glutamyl transferase (GGT) 
> alanine transaminase (ALT)] and 15/17 (93.75%) were on 
HAART. Fifteen patients had mild hepatitis (ALT five times 
the upper limit of normal), all of which were on HAART, and 
four patients had frank hepatitis (ALT 10 times the upper 
limit of normal), three of which were on HAART. Three 
patients developed hepatitis while on multidrug-resistant 
tuberculosis treatment. 
Various forms of thyroid disease were found in 95 patients. 
Seventy-eight patients in the sample (22.3%) had thyroid 
disease prior to initiating multidrug-resistant tuberculosis 
treatment, and 17 patients in the sample (4.8%) developed 
thyroid disease while on treatment. Sixty-five (68.4%) of the 
95 affected patients had normal thyroid-stimulating hormone 
(TSH) levels, with low T4 (free thyroxine) levels, or “sick 
euthyroid syndrome”. Clinical hypothyroidism was found in 
27 patients, two patients had subclinical hypothyroidism, 
and one patient had subclinical hyperthyroidism. Of the 17 
patients who developed thyroid disease while on multidrug-
resistant tuberculosis treatment, 12 were HIV positive, and 
11 were on HAART.
Ten patients developed renal dysfunction while on treatment. 
Four had prerenal failure, while six had intrinsic renal failure. 
Eight of these ten patients were HIV positive and on HAART.
Fifteen patients were diabetic, of whom 6 (40%) experienced 
at least one episode of worsening glycaemic control or 
dysglycaemia. HIV status and HAART use were not found to 
be significantly associated with the dysglycaemia incidence 
(p-value = 0.143). 
Discussion
Adverse events related to certain drugs that were used 
for multidrug-resistant tuberculosis, e.g. ototoxicity from 
aminoglycoside use, are well recognised.13 Less common 
adverse effects, e.g. severe psychiatric manifestations with 
the use of cycloserine, have been reported.14 The WHO has 
published a list of adverse affects and the drugs with which 
they are associated, for patients with multidrug-resistant 
tuberculosis and HIV co-infection who are being managed 
with anti-tuberculosis drugs and HAART,7 to assist clinicians. 
A few documented international studies investigating 
the adverse effects of multidrug-resistant tuberculosis 
treatment in ambulant patients have been conducted in 
Europe, the Middle East and South America.8-11 However, 
these findings may not be applicable in the South African 
context, because of the high proportion of patients 
who are co-infected with HIV. Co-morbidity, due to HIV 
infection and treatment with HAART, may alter the profile 
of adverse events. Inter-study differences, pertaining to the 
most common adverse effects that were reported, make 
these studies difficult to compare. The study conducted 
in Istanbul, Turkey, from 1992-2004 on 263 patients with 
multidrug-resistant tuberculosis revealed ototoxicity (42%), 
psychiatric disorders (21%), gastrointestinal disturbances 
(14%), arthralgia (11%), epileptic seizures (10%), hepatitis 
(5%), and dermatological effects (4.5%).10 By comparison, 
the study conducted in Lima, Peru, from 1996-1998 on 60 
patients with multidrug-resistant tuberculosis reported mild 
gastritis (100%), dermatological effects (43%), peripheral 
neuropathy (17%), depression (18%), and anxiety (11%).11 
These studies did not investigate the prevalence of HIV co-
infection or the effects of HAART on the adverse events 
profile. Table IV presents the findings of these cited studies 
regarding the adverse event profiles of multidrug-resistant 
tuberculosis treatment in various countries, as well as 
the WHO guidelines on the adverse events of multidrug-
resistant tuberculosis treatment and HAART.
A South African study of 665 in-patients with multidrug-
resistant tuberculosis conducted in 2005 in Cape Town, 
found that among patients who were less than 60 years old, 
those who were co-infected with HIV were more likely to be 
admitted with adverse events than those without HIV co-
infection. 6 It was also found that within the group that was 
HIV infected, patients who were receiving HAART were more 
likely to be admitted with adverse events, than patients who 
were not on HAART.6 In this study, only adverse events that 
were severe enough to warrant admission were studied, 
and thus may not accurately reflect the adverse events 
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profile experienced by the ambulatory patients. 
In our study, the HIV and multidrug-resistant tuberculosis 
co-infection rate (74.5%) was higher than the rate 
recently reported in a study based in the Western Cape 
(34%), which looked at patients who were admitted with 
multidrug-resistant tuberculosis.15 The Western Cape study 
also reported a lower HIV co-infection rate in in-patients 
with multidrug-resistant tuberculosis, compared with in-
patients with drug-sensitive tuberculosis.15 This difference 
may reflect the higher HIV disease burden in the KwaZulu-
Natal province, or socio-economic differences between the 
regions. The percentage of patients who were HIV positive 
on HAART (85%) was also higher than that reported in the 
Western Cape study (74%).15 However, it is still below the 
Department of Health target, which is to have all patients 
who have multidrug-resistant tuberculosis and co-infected 
HIV on antiretroviral therapy, if indicated.2 
In this study, it was necessary to include the occurrence of 
adverse events prior to initiation of treatment for multidrug-
resistant tuberculosis, because adverse events may be due 
to several factors. These may occur because of the effects 
of current or previous standard tuberculosis treatment,12 or 
as a manifestation of HIV infection itself or HAART use.7,12 
In addition, some drugs that are used to treat multidrug-
resistant tuberculosis and HIV can potentially produce 
similar adverse events.7 Also, the occurrence of certain 
adverse events are known to be linked to the use of certain 
HAART drugs7 (see Table IV). As one of the objectives of this 
study was to establish an adverse events profile in the study 
population, which had not been carried out previously, all 
adverse events that were recorded in the patient files were 
included.
According to the current tuberculosis management 
guidelines, “routine culture and first-line drug-susceptibility 
testing (DST) should be done for all-high risk groups, such 
as retreatment patients with tuberculosis, new patients with 
tuberculosis who remain sputum-smear positive after two 
months and symptomatic close contact of patients with 
confirmed multidrug-resistant tuberculosis. Second-line 
DST should be conducted on all patients with confirmed 
multidrug-resistant tuberculosis.”4 
Table IV: Known adverse effects of HAART and multidrug-resistant tuberculosis
HAART drugs linked 
to specific adverse 
events
Anti-tuberculosis drugs 




adverse effects  
(WHO guideline)12
Adverse effects reported in 
other studies8-11
Common adverse effects 








Peripheral neuropathy Peripheral neuropathy Peripheral neuropathy
Aminogylcosides (kanamycin) Hearing loss and vestibular 
disturbances
Hearing loss and vestibular 
disturbances
 
EFV Ethionamide, terizidone Psychoses Psychoses  
EFV Fluoroquinolones Depression Depression Depression




Ethionamide Gastrointestinal symptoms 
other than gastritis (nausea, 
vomiting and diarrhoea)
Gastrointestinal symptoms 
other than gastritis (nausea, 
vomiting and diarrhoea)
Gastrointestinal symptoms 
other than gastritis (nausea, 
vomiting and diarrhoea)
All ART drugs Ethionamide, pyrazinamide Gastritis (upper abdomi-
nal pain or discomfort, 
dyspepsia)
Gastritis (upper abdominal 










TDF Aminogylcosides (kanamycin) Renal toxicity   Renal toxicity
Pyrazinamide Arthralgia Arthralgia  
    Anxiety  
NVP, EFV, D4T Ethambutol, pyrazinamide   Stevens-Johnson syndrome  






D4T: stavudine, EFV: efavirenz, NVP: nevirapine, TDF: tenofovir
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This is a point of concern, as the results of this study showed 
that 45% (158/350) of patients with multidrug-resistant 
tuberculosis were found to have multidrug-resistant 
tuberculosis prior to any previous tuberculosis treatment, 
or while on their first tuberculosis treatment. Thus, usually 
these patients are not tested for tuberculosis resistance at 
their initial presentation, unless they are close contacts of 
confirmed patients with multidrug-resistant tuberculosis. 
Therefore, most of them are tested two months after starting 
standard treatment, if they remain sputum-smear positive. 
These patients could potentially continue to infect other 
members of their families and community prior to starting 
appropriate therapy. A further 40% (143/350) of patients 
were diagnosed with multidrug-resistant tuberculosis while 
receiving their first retreatment regimen. This rate is much 
higher than that reported in other studies, and suggests 
the need to either implement drug sensitivity testing for all 
first-time patients with tuberculosis, or find a way to identify 
high-risk patients when they present with tuberculosis for 
the first time. In this study, patients presenting with primary 
multidrug-resistant tuberculosis were statistically more 
likely to be young females who were HIV positive. However, 
there was a significant association with positive HIV status 
and a positive tuberculosis contact history in males with 
primary multidrug-resistant tuberculosis. Therefore, these 
subgroups may represent high-risk groups who should be 
offered drug sensitivity testing on initial presentation.
It was also of concern that there was little available 
information on the patients’ HIV treatment and monitoring 
in the records. Currently, patients attend HIV clinics near 
their homes where their treatment cards are held, while also 
attending the centralised multidrug-resistant tuberculosis 
clinic. In this study population, information was lacking 
on CD4 counts and viral loads. The WHO has advocated 
that multidrug-resistant tuberculosis and HIV treatment be 
combined at a single clinic to improve the management 
of both conditions.7 Since a single laboratory service 
performs pathology tests for both clinics, using the patient’s 
identification number would also allow doctors and nurses 
in either clinic to document all results. 
In this study, patients who were HIV positive were more likely 
to experience adverse effects than patients who were HIV 
negative. This finding is similar to that of a previous South 
African study.6 The likelihood ratios for the occurrence of 
most adverse events was greater in patients who were HIV 
positive on HAART, compared with those not on HAART, 
although due to small numbers in these subgroups, this was 
not statistically significant. In this study, the adverse events 
profile and the frequencies of the adverse events were 
dissimilar to those reported in other studies (see Table IV). The 
overall occurrence of adverse events in patients who were 
on HAART, compared with those who were not on HAART, 
was not statistically significant. Thus, the concomitant use 
of HAART and multidrug-resistant tuberculosis drugs does 
not conclusively account for differences in the adverse 
events profile found in our study, when compared with that 
of other studies. The possibility of under-reporting in this, 
as well as other studies, must be considered. In the future, 
under-reporting might be mitigated by the development of 
a recording instrument, similar to the one that was used 
to collect data for this study. Such a tool could be used 
by clinic doctors to quickly and objectively record adverse 
effects in a standardised way, and prompt clinicians to 
enquire about certain adverse effects that patients might 
not have reported. 
The association of thyroid disease with tuberculosis is known. 
Mostly, it is due to rifampicin-induced hypothyroidism16 and 
thyroid suppression due to chronic illness. In a few cases, it 
is due to thyroid tuberculosis. Therefore, there is a need to 
monitor thyroid functions periodically. In this study, the high 
percentage of thyroid disease 95/350 (22.3%) was thought 
to be the result of the direct effects of a chronic disorder, like 
tuberculosis, on the thyroid and/or the suppressive effect 
of ethionamide or stavudine on thyroid function.17,18 In this 
study, “sick euthyroid syndrome” was the most common 
finding. In sick euthyroid syndrome,TSH levels are usually 
normal, with low T4 levels. The syndrome is thought to be 
due to the temporary suppressive effects on the thyroid by 
certain drugs, but it is also independently associated with 
chronic illnesses, such as tuberculosis.19,20
Renal failure in the study group was mild to moderate. 
No patients required dialysis. In most cases, the dose of 
kanamycin was reduced in frequency from five injections 
per week to three, and the patients were monitored carefully.
The incidence of dysglycaemic events in more than a 
third of the patients with diabetes (80% of which were 
HIV  negative) is not linked to any known adverse effect of 
multidrug-resistant tuberculosis drugs. However, diabetic 
treatment compliance, dietary compliance, and a chronic 
state of ill health are all confounding factors that can affect 
glycaemic control, and these factors were not controlled in 
this study.
Conclusion 
The high percentage of patients who are found to be 
multidrug-resistant tuberculosis-positive de novo, or while 
on standard tuberculosis treatment, suggests that drug 
sensitivity testing for all patients with tuberculosis should 
be considered. Although all multidrug-resistant tuberculosis 
cases are probably due to “acquired resistance”, i.e. 
resistance to a drug to which the organism was previously 
susceptible,21 it must be considered that some treatment-
naïve patients can present for the first time with multidrug-
resistant tuberculosis. It was not possible to determine 
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the extent to which this might have been true in this study 
population. However, it would be advisable to investigate 
this further. Fortunately, the GenXpert®, which rapidly 
detects rifampicin-resistance based on gene profiling of 
the mycobacterium, is available in a number of hospitals 
throughout KwaZulu-Natal. Results from this study suggest 
that there is a need to implement this technology in all 
institutions in which tuberculosis is diagnosed. 
The findings of this study support the current national 
policy that all patients who have tuberculosis should be 
tested for HIV, and that all patients who are HIV positive 
with multidrug-resistant tuberculosis should be on HAART. 
Patients who were HIV positive and who are on multidrug-
resistant tuberculosis treatment were statistically more likely 
to experience certain adverse events more so than patients 
who were HIV-negative. Clinicians need to be vigilant 
when looking for adverse events, to inform patients of the 
possibility of adverse events developing, and to manage 
adverse events in order to encourage patients to remain 
adherent to their treatment. The reporting of adverse events 
to the Department of Health should be encouraged, as 
such reports contribute both to local and global treatment 
surveillance. 
The possibility of under-reporting of adverse events might be 
mitigated by the development of a standardised recording 
instrument for use by clinic doctors and nursing staff.
Some of the findings suggested by this study could be 
confirmed by a case-controlled cohort study, using the 
three patient subgroups of patients identified, i.e. those with 
multidrug-resistant tuberculosis only, those co-infected 
with multidrug-resistant tuberculosis and HIV who were 
on HAART, and those co-infected with multidrug-resistant 
tuberculosis and HIV who were not on HAART.
Limitations
As a result of patients attending separate HIV and 
multidrug-resistant tuberculosis clinics, there was poor 
recording of current HIV treatment and monitoring results 
in the multidrug-resistant tuberculosis clinic files. A further 
limitation was the fact that the recorded adverse events 
were based on clinical assessments that were made by 
the treating doctors. Therefore, to some degree, they 
were subjective. However, reporting in this manner is in 
accordance with WHO tuberculosis treatment guidelines. 
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